Mikhail Mogutov, Ph.D.
Chairman of the Board of Directors
Chief Executive Officer and founder of Bioprocess Capital Ventures
Dr. Mogutov currently serves as the Chairman of the Board of Directors and is the Chief Executive Officer and founder of Bioprocess Capital Ventures. Mikhail Dr. Mogutov has been successful entrepreneur in different industries for more than 20 years and has 35 publications and 5 patents to his name. From 1979 to 1989, he was involved in Molecular Genetics and Biotechnology. In 1988, Dr. Mogutov co- founded Mutual Venture Fund «Bioprocess Capital Ventures». In the past, he has managed large Russian companies such as OJSC Tomsky Petrochemical Plant, OJSC Volganeft, JSCB Promtorgbank and others, and has participated in the establishment and development of OJSC United Heavy Machinary Plants. Dr. Mogutov is a member of Board of Trustees of the Y.A. Ovchinnikov Russian Society of Biotechnologists.
Vladimir Tezov, M.D., MBA
Vladimir Tezov is member of the Board of Directors of many biotechnological and pharmaceutical companies. From 1995 to 2001, Mr. Tezov managed corporate services in the Energomash Corporation, participated in establishment and structuring of the holding company and served as a member of Board of Directors in several plants. From 2002 to 2006, he managed projects in Mergers and Acquisitions markets and worked as independent consultant on the prevention of hostile takeovers. In 2006 Vladimir became CEO of Management Company Bioprocess Capital Partners. He is now involved in the activities of Bioprocess Capital Ventures with assets equal to 3.6 million rubles and makes decisions on all Company’s activities.
Andrei Gudkov, Ph.D., D. Sci.
Dr. Gudkov has served as Cleveland BioLabs’ Chief Scientific Officer and as a director since the company’s inception in June 2003. He is also Senior VP Basic Science and Chair, Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, NY. Prior to 1990, he worked at The National Cancer Research Center in Moscow (USSR) where he led a broad research program focused on virology and cancer drug resistance. In 1990, he reestablished his lab at the University of Illinois at Chicago where he became a tenured faculty member in the Department of Molecular Genetics. His lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic where he became Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. In 2007, Dr. Gudkov accepted the position of Senior VP Basic Science and Chair, Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, NY.
Ms. Kasimova has been Director of Strategy and Investment at BioProcess Capital Partners since 2010. Kasimova has more than 10 years of experience in various financial positions with a focus on corporate finance and mergers and acquisitions. Ms. Kasimova also currently serves on the board of directors of seven biotechnological, pharmaceutical and telecom companies. Prior to this she was a Vice President at NRG Private Equity, the management company of a private equity fund with over $200 million in assets under management. From 2005 to 2008, Ms. Kasimova was Director of J&P Capital, the Corporate Finance and Investment Department of J’son & Partners Consulting, where she managed more than 50 corporate finance and investment projects. From 2003 to 2005, she served in various positions in the Financial Department at Ulyanovsk-GSM, a cellular operator, ending her tenure as Chief Economist. She was also involved in number of marketing & consultancy projects as a team leader.
She holds degrees in investment management and linguistics from Ulyanovsk State University and is certified by the Russian state securities and exchange commission as an investment fund manager and executive.
Andrei Leonov, Ph.D.
Dr. Leonov is Chief Executive Officer of 3 pharmaceutical companies: Incuron, LLC, Tartis-Ageing, LLC and Oncotartis, LLC since 2010.
In 2005, Dr. Leonov was invited to join Bioprocess Holdings as Project Manager of Pharmapark, LLC. Dr. Leonov is one of the architects of the concept of the Bioprocess Capital Ventures Fund and he served as the Fund’s Investment Manager from 2008 until 2010.
Prior to joining Bioprocess, Dr. Leonov was a Clinical Research Associate at Novartis (Switzerland).
Dr. Leonov received his Ph.D. in Chemistry from Moscow State University. In 1999 – 2003, he researched at Moscow State University with intense collaboration with Max Planck Institute of Molecular Genetics in Berlin, Germany. Dr. Leonov has a number of scientific publications and patents.